Home > Insider Trading > Filing (0001209191-20-042311)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178879	Amicus Therapeutics Inc.	FOLD	Pharmaceutical Preparations (2834)	200422823

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1601896	Jay Barth	C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-07-09	11,559	$8.61	174,763	No	4	M	Direct
Common Stock	Acquisiton	2020-07-09	8,850	$9.03	183,613	No	4	M	Direct
Common Stock	Acquisiton	2020-07-09	6,142	$10.04	189,755	No	4	M	Direct
Common Stock	Acquisiton	2020-07-09	17,896	$12.28	207,651	No	4	M	Direct
Common Stock	Disposition	2020-07-09	44,447	$15.92	163,204	No	4	S	Direct
Common Stock	Acquisiton	2020-07-10	28,843	$5.13	192,047	No	4	M	Direct
Common Stock	Disposition	2020-07-10	28,843	$15.65	163,204	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (right to buy)	Disposition	2020-07-09	11,559	$0.00	11,559	$8.61
Common Stock	Stock Options (right to buy)	Disposition	2020-07-09	8,850	$0.00	8,850	$9.03
Common Stock	Stock Options (right to buy)	Disposition	2020-07-09	6,142	$0.00	6,142	$10.04
Common Stock	Stock Options (right to buy)	Disposition	2020-07-09	17,896	$0.00	17,896	$12.28
Common Stock	Stock Options (right to buy)	Disposition	2020-07-10	28,843	$0.00	28,843	$5.13

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2025-01-02	No	4	M	Direct
0	2026-01-04	No	4	M	Direct
55,099	2029-01-02	No	4	M	Direct
0	2025-06-01	No	4	M	Direct
11,778	2027-01-03	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	20	Indirect	By Daughter

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $15.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.49 to $15.91 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of the transaction date.
As of July 9, 2020, 9,584 options were fully vested and exercisable and 51,657 remained unvested from this grant.
As of July 10, 2020, 31,785 options were fully vested and exercisable and 8,836 remained unvested from this grant.